{"id":"NCT05028582","sponsor":"Arcutis Biotherapeutics, Inc.","briefTitle":"Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)","officialTitle":"A Randomized tRial Employing topiCal roflumilasT Foam to Treat Scalp Psoriasis (ARRECTOR)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-08-24","primaryCompletion":"2022-06-03","completion":"2022-06-03","firstPosted":"2021-08-31","resultsPosted":"2025-07-17","lastUpdate":"2025-07-17"},"enrollment":432,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Scalp Psoriasis"],"interventions":[{"type":"DRUG","name":"Roflumilast Foam 0.3%","otherNames":["ARQ-154 0.3%"]},{"type":"DRUG","name":"Vehicle Foam","otherNames":[]}],"arms":[{"label":"Roflumilast Foam 0.3%","type":"ACTIVE_COMPARATOR"},{"label":"Vehicle Foam","type":"PLACEBO_COMPARATOR"}],"summary":"This was a parallel group, double blind, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-154) 0.3% foam vs vehicle foam applied once daily (qd) for 8 weeks by participants with plaque psoriasis of the scalp and body.","primaryOutcome":{"measure":"Achievement of Scalp Investigator Global Assessment (S-IGA) \"Success\" at Week 8","timeFrame":"Week 8","effectByArm":[{"arm":"Roflumilast Foam 0.3%","deltaMin":66.4,"sd":null},{"arm":"Vehicle Foam","deltaMin":27.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":7},"locations":{"siteCount":49,"countries":["United States","Canada"]},"refs":{"pmids":["40332898"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":281},"commonTop":[]}}